Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctions

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 10, 2010, Pages 1009-1022

  Bhuiyan, Md Shenuarin ^a   Tagashira, Hideaki ^a   Shioda, Norifumi ^a   Fukunaga, Kohji ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Endothelial nitric oxide synthase (eNOS); Myocardial hypertrophy; Ovariectomy; Protein kinase B (Akt); Sigma 1 receptor (Sig 1R)

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; BETA TUBULIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUVOXAMINE MALEATE; PROTEIN KINASE B; SIGMA 1 OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; GENE EXPRESSION; HEART INJURY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; MALE; NONHUMAN; PRESSURE; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; ANISOLES; BLOOD PRESSURE; CARDIOTONIC AGENTS; FEMALE; FLUVOXAMINE; HEART; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; OVARIECTOMY; PROPYLAMINES; RATS; RATS, WISTAR; RECEPTORS, GLYCINE; RECEPTORS, SIGMA; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 77957056995     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.509348     Document Type: Article

References (58)

1. Martin WR, Eades CG, Thompson JA, et al. The effects of morphine and morphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976;197:517-532
2. Matsumoto RR, Liu Y, Lerner M, et al. Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol 2003;469:1-12
3. Maurice T, Martin-Fardon R, Romieu P, Matsumoto RR. Sigma1 (s1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002;26:499-527
4. Aram JA, Martin D, Tomezyk M, et al. Neocortical epileptogenesis in vitro: studies with N-methyl-D-aspartate, phencyclidine, sigma and dextromethorphan receptor ligands. J Pharmacol Exp Ther 1989;248:320-328
5. Martin BR, Katzen JS, Woods JA, et al. Stereoisomers of [3H]-N-allylnormetazocine bind to different sties in mouse brain. J Pharmacol Exp Ther 1984;231(3):539-544
6. Ela C, Barg J, Vogel Z, et al. Sigma receptor ligands modulate contractility, Ca++ influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther 1994;269:1300-1309
7. Novakova M, Ela C, Barg J, et al. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol 1995;286:19-30
8. Novakova M, Ela C, Bowen WD, et al. Highly selective sigma receptor ligands elevate inositol 1,4,5-trisphosphate production in rat cardiac myocytes. Eur J Pharmacol 1998;353:315-327
9. Ela C, Hasin Y, Eilam Y. Apparent desensitization of a sigma receptor sub-population in neonatal rat cardiac myocytes by pre-treatment with sigma receptor ligands. Eur J Pharmacol 1996;295:275-280
10. Novokova M, Bruderova V, Sulova Z, et al. Modulation of expression of the sigma receptors in the heart of rat and mouse in normal and pathological conditions. Gen Physiol Biophys 2007;26:110-117
11. Fialova K, Krizanova O, Jarkovsky J, Novakova M. Apparent desensitization of the effects of sigma receptor ligand haloperidol in isolated rat and guinea pig hearts after chronic treatment. Can J Physiol Pharmacol 2009;87:1019-1027
12. Hellewell SB, Bruce A, Feinstein G, et al. Rat liver and kidney contain high densities of sigma1 and sigma2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994;268:9-18
13. Maurice T, Gregoire C, Espallergues J. Neuro(active)steroids actions at the neuromodulatory sigma1 (s1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol Biochem Behav 2006;84:581-597
14. Bhuiyan MS, Fukunaga K. Stimulation of sigma-1 receptor signaling by dehydroepiandrosterone ameliorates pressure overload-induced hypertrophy and dysfunctions in ovariectomized rats. Expert Opin Ther Targets 2009;13:1253-1265
15. Bhuiyan MS, Fukunaga K. Stimulation of sigma-1 receptor by dehydroepiandrosterone ameliorates hypertension-induced kidney hypertrophy in ovariectomized rats. Exp Biol Med 2010;235:356-364
16. Bhuiyan MS, Tagashira H, Fukunaga K. Dehydroepiandrosterone mediated stimulation of sigma-1 receptor activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding. Cardiovasc Ther 2010; published online 11 June 2010, DOI: 10.1111/j.1755-5922.2010.00196.x
17. Ramamoorthy JD, Ramamoorthy S, Mahesh VB, et al. Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. Endocrinology 1995;136:924-932
18. Fontanilla D, Johannessen M, Hajipour AR, et al. The hallucinogen N, N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science 2009;323:934-937
19. Baulieu EE. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 1998;23:963-987
20. Waterhouse RN, Chang RC, Atuahene N, Collier TL. In vitro and in vivo binding of neuroactive steroids to the sigma-1 receptor as measured with the positron emission tomography radioligand [18F]FPS. Synapse 2007;61(7):540-546
21. Collier TL, Waterhouse RN, Kassiou M. Imaging sigma receptors: applications in drug development. Curr Pharm Des 2007;13:51-72 (Pubitemid 46085300)
22. Monnet FP, Maurice T. The sigma1 protein as a target for the non-genomic effects of neuro(active) steroids: molecular, physiological, and behavioral aspects. J Pharmacol Sci 2006;100:93-118
23. Ishikawa M, Ishiwata K, Ishii K, et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C] SA4503. Biol Psychiatry 2007;62:878-883
24. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-798
25. Narita N, Hashimoto K, Tomitaka S, Minoabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996;307:117-119
26. Bhuiyan MS, Shioda N, Fukunaga K. Ovariectomy augments pressure overload-induced hypertrophy associated with changes in Akt and nitric oxide synthase signaling pathways in female rats. Am J Physiol Endocrinol Metab 2007;293:E1606-14
27. Bhuiyan MS, Shioda N, Shibuya M, et al. Activation of endothelial nitric oxide synthase by a vanadium compound ameliorates pressure overload-induced cardiac injury in ovariectomized rats. Hypertension 2009;53:57-63
28. Bhuiyan MS, Fukunaga K. Characterization of an animal model of postmenopausal cardiac hypertrophy and novel mechanisms responsible for cardiac decompensation using ovariectomized pressure-overloaded rats. Menopause 2010;17:213-221
29. Shioda N, Yamamoto Y, Watanabe M, et al. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci 2010;30(8):3146-3155
30. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell 2007;131:596-610
31. Zeng G, Nystrom FH, Ravichandran LV, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000;101:1539-1545
32. Dumont M, Lemaire S. Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma2 binding sites in rat heart membrane preparations. Eur J Pharmacol 1991;209:245-248
33. Zamanillo D, Andreu F, Ovalle S, et al. Up-regulation of sigma1 receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand. Neurosci Lett 2000;282:169-172
34. Shirayama Y, Nishikawa T, Umino A, Takahashi K. p-Chlophenylalanine reversible reduction of sigma binding sites by chronic imipramine treatment in rat brain. Eur J Pharmacol 1993;237:117-126
35. Inoue A, Sugita S, Shoji H, et al. Repeated haloperidol treatment decreases sigma1 receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur J Pharmacol 2000;401:307-316
36. Yamamoto H, Miura R, Yamamoto T, et al. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett 1999;445:19-22
37. Nakano M, Osada K, Misonoo A, et al. Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473- phosphorylation of Akt-1 in PC12 cells. Life Sci 2010;86:309-314
38. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res 2004;64:4875-4886
39. Wang L, Duncan G. Silencing of sigma-1 receptor induces cell death in human lens cells. Exp Cell Res 2006;312:1439-1446
40. Houser SR, Molkentin JD. Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 2008;1(25):pe31
41. Monnet FP. Sigma-1 receptor as regulator of neuronal intracellular Ca2+: clinical and therapeutic relevance. Biol Cell 2005;97:873-883
42. Tchedre KT, Huang RQ, Dibas A, et al. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci 2008;49(11):4993-5002
43. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. MAM: more than just a housekeeper. Trends Cell Biol 2009;19:81-88
44. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci USA 2001;98:491-496
45. Hayashi M, Yamaji Y, Nakazato Y, Saruta T. The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells. Hypertens Res 2000;23:521-525
46. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009;9:197-204
47. Cooper GL. The safety of fluoxetine: an up-date. Br J Psychiatry 1988;153:77-86
48. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;46(Suppl 2):42-44
49. Glassman AH, OConnor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709
50. Swenson JR, OConnor CM, Barton D, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003;92:1271-1276
51. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 2005;111:250-253
52. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108:939-944
53. Shores MM, Pascualy M, Lewis NL, et al. Short-term sertraline treatment suppresses sympathetic nervous system activity in healthy human subjects. Psychoneuroendocrinology 2001;26:433-439
54. Golding M, Kotlyar M, Carson SW, et al. Effects of paroxetine on cardiovascular response to mental stress in subjects with a history of coronary artery disease and no psychiatric diagnoses. Psychopharmacology 2005;182:321-326
55. Golding M, Kotlyar M, Garbutt JC, et al. Paroxetine modulates psychological and sympathetic responses during public speaking. J Clin Psychopharmacol 2002;22:98-99
56. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006;119:113-116
57. Serebruany VL, Gurbel PA, OConnor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001;43:453-462
58. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898